Hope on the horizon: Emerging therapies for hepatitis D

doi:10.4254/wjh.v17.i6.107963

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2948)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

1832

Figures (1-1)

182

Tables (1-1)

169

Sum=2278

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

103

Download

417

Sum=520

Jun 27, 2025 (publication date) through Mar 1, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jun 27, 2025; 17(6): 107963
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.107963

Hope on the horizon: Emerging therapies for hepatitis D

Zaigham Abbas, Minaam Abbas

Zaigham Abbas, Department of Hepatogastroenterology, Dr. Ziauddin University Hospital Clifton, Karachi 75600, Sindh, Pakistan

Minaam Abbas, Department of Medicine, University of Cambridge, Cambridge CB2 0SP, United Kingdom

Co-first authors: Zaigham Abbas and Minaam Abbas.

Author contributions: Abbas Z and Abbas M contributed equally to this work.

Conflict-of-interest statement: Abbas Z contributed patients to the D-LIVR study. He is the principal investigator from his site for HHoo3, ECLIPSE 1, and 3 studies mentioned in the manuscript.

Corresponding author: Zaigham Abbas, AGAF, FACG, FACP, FRCP, Head, Professor, Department of Hepatogastroenterology, Dr. Ziauddin University Hospital Clifton, Karachi 75600, Sindh, Pakistan. drzabbas@gmail.com

Received: April 2, 2025
Revised: April 22, 2025
Accepted: June 7, 2025
Published online: June 27, 2025
Processing time: 86 Days and 3.6 Hours

Core Tip

Core Tip: New therapeutic options for hepatitis D are emerging, offering hope for improved treatment outcomes. Pegylated interferon-alpha is currently the primary treatment for hepatitis D, but it has limitations, including significant adverse effects and low response rates. Several novel therapies are being developed. Bulevirtide, HH003, and tobevibart are entry inhibitors. Other drugs include pegylated interferon-lambda, a type III interferon; lonafarnib, a prenylation inhibitor that prevents viral replication with synergistic effects when combined with pegylated interferon-alpha; REP 2139, a nucleic acid polymer that inhibits virus entry and replication; and small interfering RNAs, including elebsiran that interfere with translation of hepatitis B virus RNA.